EBV+ B lymphoma cell lines from patients with post-transplant lymphoproliferative disease are resistant to TRAIL-induced apoptosis

American Journal of Transplantation

Volumn 6, Issue 5 I, 2006, Pages 976-985

  Snow, A L ^a   Vaysberg, M ^a   Krams, S M ^a   Martinez, O M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; B cell; EBV; Lymphoma; PTLD; TRAIL

Indexed keywords

CASPASE 8; DEATH RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; CHOP PROTOCOL; CYCLOPHOSPHAMIDE; DOXORUBICIN; MEMBRANE PROTEIN; PREDNISONE; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

APOPTOSIS; ARTICLE; CELL SURFACE; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; ENZYME ACTIVATION; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; LYMPHOMA CELL LINE; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; B CELL LYMPHOMA; FLOW CYTOMETRY; ISOLATION AND PURIFICATION; PATHOLOGY; TUMOR CELL LINE; VIROLOGY; VIRUS INFECTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPSTEIN-BARR VIRUS INFECTIONS; FLOW CYTOMETRY; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MEMBRANE GLYCOPROTEINS; PREDNISONE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; VINCRISTINE;

EID: 33745232513     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01295.x     Document Type: Article

References (28)

1. Klein G. Post-transplantation lymphoproliferative disease. Introduction. Springer Semin Immunopathol 1998; 20: 319-323.
2. Paya CV, Fung JJ, Nalesnik MA et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68: 1517-1525.
3. Gottschalk S, Heslop HE, Rooney CM. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma 2005; 46: 1-10.
4. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-776.
5. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004; 4: 333-339.
6. Johnsen AC, Haux J, Steinkjer B et al. Regulation of APO-2 ligand/trail expression in NK cells-involvement in NK cell-mediated cytotoxicity. Cytokine 1999; 11: 664-672.
7. Kayagaki N, Yamaguchi N, NakayamaM, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999; 189: 1451-1460.
8. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168: 1356-1361.
9. Janssen EM, Droin NM, Lemmens EE et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005; 434: 88-93.
10. Takeda K, Smyth MJ, Cretney E et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002; 195: 161-169.
11. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2: 420-430.
12. Beatty PR, Krams SM, Martinez OM. Involvement of IL-10 in the autonomous growth of EBV-transformed B-cell lines. J Immunol 1997; 158: 4045-4051.
13. Nepomuceno RR, Balatoni CE, Natkunam Y, Snow AL, Krams SM, Martinez OM. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 2003; 63: 4472-4480.
14. Snow AL, Chen LJ, Nepomuceno RR, Krams SM, Esquivel CO, Martinez OM. Resistance to Fas-mediated apoptosis in EBV-infected B cell lymphomas is due to defects in the proximal Fas signaling pathway. J Immunol 2001; 167: 5404-5411.
15. Zhang XD, Franco AV, Nguyen T, Gray CP, Hersey P. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol 2000; 164: 3961-3970.
16. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 2000; 482: 193-199.
17. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000; 288: 2351-2354.
18. Siegel RM, Frederiksen JK, Zacharias DA et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000; 288: 2354-2357.
19. Algeciras-Schimnich A, Shen L, Barnhart BC, Murmann AE, Burkhardt JK, Peter ME. Molecular ordering of the initial signaling events of CD95. Mol Cell Biol 2002; 22: 207-220.
20. Hussain A, Doucet JP, Gutierrez M et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas apoptosis in Burkitt's lymphomas with loss of multiple pro-apoptotic proteins. Haematologica 2003; 88: 167-175.
21. Mitsiades CS, Treon SP, Mitsiades N et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: Therapeutic applications. Blood 2001; 98: 795-804.
22. Olsson A, Diaz T, Aguilar-SantelisesMet al. Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D. Leukemia 2001; 15: 1868-1877.
23. Secchiero P, Tiribelli M, Barbarotto E et al. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. J Cell Physiol 2005; 205: 246-252.
24. Clodi K, Wimmer D, Li Y et al. Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells. Br J Haematol 2000; 111: 580-586.
25. Mouzakiti A, Packham G. Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines. Br J Haematol 2003; 122: 61-69.
26. Khanolkar A, Yagita H, Cannon MJ. Preferential utilization of the perforin/granzyme pathway for lysis of Epstein-Barr virus-transformed lymphoblastoid cells by virus-specific CD4+ T cells. Virology 2001; 287: 79-88.
27. Lewinsohn DM, Bement TT, Xu J et al. Human purified protein derivative-specific CD4+ T cells use both CD95-dependent and CD95-independent cytolytic mechanisms. J Immunol 1998; 160: 2374-2379.
28. Katano H, Ali MA, Patera AC et al. Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation. Blood 2004; 103: 1244-1252.